Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)

US11634495B2 · kind B2 · utility

Assignee

• MILTENYI BIOTEC B.V. & CO. KG · DE

Inventors

• Iris Bürger · Rösrath, DE
• Martin Meyer · Kürten, DE
• Andrzej Dzionek · Overath, DE

Key dates

• Filing date: Apr 6, 2018
• Grant date: Apr 25, 2023
• Expiry date: Nov 29, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to polypeptides comprising a mutant human IgG4, which mutant human IgG4 is capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing FcγRIIb/c (CD32b), but not FcγRIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgG4 with a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgG4 is capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgG1 and than a wild-type human IgG4, for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.